Bajaj Healthcare Q1 revenue up 11%; results reiterate known numbers
Domestic API sales jumped 27% but exports slipped. The press release adds nothing new beyond the board outcome.
— 1 earlier story on Bajaj Healthcare Ltd. →What's new
- Revenue ₹165.6 cr, up 11.3% YoY
- PAT ₹13.7 cr, up 15.8% YoY
- Domestic API sales grew 27%
- SEC recommended Cenobamate tablets
Why this matters
A routine confirmatory filing. The real news—domestic API growth and the Cenobamate recommendation—was already released via the board outcome. With a trailing P/E of 48 and negative trailing PAT growth, consistency in domestic API performance is the key to re-rating.
What we're watching
- Earnings call on July 21 for management commentary on export API decline
- Cenobamate tablet approval timeline and commercial launch
- Sustained domestic API momentum and margin trajectory
The full read
Bajaj Healthcare's Q1 numbers were already out. The press release today confirms revenue of ₹165.6 crore, up 11.3%; PAT of ₹13.7 crore, up 15.8%; and an EBITDA margin of 17.8%. Domestic API sales jumped 27%, while export API and formulations slipped. The filing also notes an SEC recommendation for Cenobamate tablets, a pipeline item that adds optionality but no near-term revenue. The open question is whether domestic API momentum is sustainable. Hardly a surprise. The stock trades at 48x trailing earnings. Profitability needs to follow the topline. The call on July 21 may offer clues on both fronts.
Questions answered
- What drove Bajaj Healthcare's Q1 revenue growth?
- Domestic API sales rose 27%, significantly outpacing the overall revenue growth of 11.3% YoY. Export API and formulations saw modest declines.
- Were these results a surprise?
- No, the core figures were already disclosed in the board meeting outcome earlier on July 20. This press release is a reiteration with additional commentary.
- What is the significance of the SEC recommendation for Cenobamate tablets?
- It is a regulatory milestone that, if followed by final approval, would allow Bajaj Healthcare to market Cenobamate tablets in the US, expanding its product portfolio.
- How did profitability change in Q1?
- EBITDA margin expanded to 17.8%, and PAT grew 15.8% to ₹13.7 crore, indicating improved operational efficiency.
- When is the earnings call, and what should investors look for?
- The call is on July 21 at 4:00 PM IST. Key areas include further details on domestic API growth drivers, reasons for export decline, and Cenobamate launch plans.
Bajaj Healthcare Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on BAJAJHCARE →- 20 Jul 2026 · 8:51 PM IST Bajaj Healthcare Q1 revenue up 11%; results reiterate known numbers
- 1d ago Bajaj Healthcare logs 11% revenue growth in Q1, PBT up 13%